Mirador has raised more than $400M in Financing led by ARCH Venture Partners

San Diego, CA, March 21, 2024 (Business Wire) -- Founded by Mark C. McKenna and guided by a team of seasoned executives from Prometheus Biosciences (acquired by Merck for an impressive $10.8 billion in 2023), Mirador stands at the forefront of revolutionizing precision medicine. Focused on immune-mediated inflammatory and fibrotic conditions, the company leverages its proprietary Mirador360TM development engine to propel multiple programs forward with agility. Over $400 million in financing has been secured by Mirador, led by ARCH Venture Partners.

Read full article here.